Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
This is a multi-center, open-label, dose escalation study.
Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma
DRUG: TG02 citrate
Maximum Tolerated Dose, To assess the number of patients with dose-limiting toxicities (DLT) and the dose of TG02 citrate that can be safely given to patients with CLL or SLL., 28 days
Adverse Events, The number of patients with adverse events, 28 days
The primary objective is to determine the highest dose of TG02 citrate that can be safely given to patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma.